Abstract:Ling Tang, 1 Yu-Jia Wang, 2 Yuan-Yuan Wang, 2 Shu-Tong Li, 3 Liang Kong, 3 Xue-Tao Li, 3 Ling-Ling Ma, 1 Xiu-Xiu Liu 1 1 Department of Obstetrics and Gynecology, Affiliated Zhongshan Hospital of Dalian University, Dalian, People's Republic of China; 2 Department of Pharmacy, Affiliated Zhongshan Hospital of Dalian University, Dalian, People's Republic of China; 3 School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 116600, People's Republic of China Correspondence: Ling-Ling Ma; Xiu-Xiu Liu, Department of Obstetrics and Gynecology, Affiliated Zhongshan Hospital of Dalian University, Dalian, People's Republic of China, Email ; Purpose: Ovarian cancer is a fatal gynecologic malignancy with a high rate of abdominal metastasis. Chemotherapy still has a poor clinical prognosis for ovarian cancer patients, with cell proliferation and angiogenesis leading to invasion, migration, and recurrence. To overcome these obstacles, we constructed a novel HA-modified paclitaxel and diosgenin liposome (PEG-TK-HA-PDLPs) using two novel functional materials, DSPE-PEG 2000 -HA and DSPE-PEG 2000 -TK-PEG 5000 , to specifically deliver the drugs to the tumor site in order to reduce OC cell proliferation and anti-angiogenic generation, thereby inhibiting invasion and migration. Methods and Results: PEG-TK-HA-PDLPs were prepared by film dispersion, with ideal physicochemical properties and exhibits active targeting for enhanced cellular uptake. The ZIP synergy score for PTX and Dios was calculated using the online SynergyFinder software to be 3.15, indicating synergy. In vitro results showed that PEG-TK-HA-PDLPs were highly cytotoxic to ID8 cells, induced ID8 cell apoptosis, and inhibited ID8 cell migration and invasion. In vivo studies showed that PEG-TK-HA-PDLPs could prolong the circulation time in the blood, accumulate significantly in the tumor site, and effectively fight against angiogenesis with significant anti-tumor effects. Conclusion: The production of PEG-TK-HA-PDLPs is an effective strategy for the treatment of OC. Keywords: ovarian cancer, functional liposomes, paclitaxel, diosgenin, ROS-response, HA It is estimated that ovarian cancer (OC) accounted for 53.60% of its deaths in 2012 and 68.46% of its deaths in 2035 (an increase of 14.86%), making it the highest case-to-death ratio among gynecological cancers. 1,2 Currently, the main treatment for OC is surgical removal of the tumor followed by a combination of cisplatin and paclitaxel chemotherapy. 3,4 However, 80% of patients with advanced OC cancer will eventually relapse and have metastasis. In addition, relapsed patients develop resistance and severe side effects after receiving chemotherapy, and there has been little improvement in the survival of OC patients over the past three decades. 5–7 This underscores the need to provide novel treatments to address these side effects. To this end, new treatment options such as molecular targets are being investigated in OC clinical trials to combat OC. 8,9 Nevertheless, there are still some problems with these targeted drugs, such as insufficient circulation time of the drug in vivo and insignificant target specificity. Therefore, it is necessary to find more effective carrier systems that utilize nano-carriers to improve drug delivery efficiency and inhibit tumor cell proliferation and metastasis. Extensive peritoneal dissemination of OC cells can lead to inoperable metastatic lesions resulting in patient death, which is a major clinical problem in the treatment of OC. 10,11 When patients with ovarian cancer are diagnosed at an early stage, confined to one or both ovaries, less than 10% will die as a result. 12,13 Based on these studies suggest that metastasis is a major cause of high mortality from ovarian cancer and that inhibiting ovarian cancer metastasis is critical to the clinical management of this daunting disease. Unlike normal tissues, the tumor microenvironment (TME) has interstitial high pressure and low convection due to resistance, making it impossible for chemicals to break through the body's blood and cellular barriers to reach the tumor site and to accumulate at the tumor site, which leads to the synthesis of a variety of stimulus-sensitive nanoparticles used for chemotherapy. 14 Biocompatible and biodegradable liposomes self-assembled from amphiphiles are representative carriers for anticancer drug delivery and may be the most promising tools for cancer chemotherapy. 15 Suitable functional liposomes are useful tools to improve drug stability and bioavailability as well as targeted delivery to the tu -Abstract Truncated-

Correction to “paclitaxel and Tacrolimus Coencapsulated Polymeric Micelles That Enhance the Therapeutic Effect of Drug-Resistant Ovarian Cancer”

Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.

Tumor-Targeting Polycaprolactone Nanoparticles with Codelivery of Paclitaxel and IR780 for Combinational Therapy of Drug-Resistant Ovarian Cancer

Correction to “Lactoferrin-Modified Gambogic Acid Liposomes for Colorectal Cancer Treatment”

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

Correction to Intracellular Fate of Nanoparticles with Polydopamine Surface Engineering and a Novel Strategy for Anti-Exocytosis Enhanced, Lysosome Impairment-Based Cancer Therapy

Deoxycholic acid-modified chitooligosaccharide/mPEG-PDLLA mixed micelles loaded with paclitaxel for enhanced antitumor efficacy.

Correction to Targeting Osteocytes to Attenuate Early Breast Cancer Bone Metastasis by Theranostic Upconversion Nanoparticles with Responsive Plumbagin Release

Correction to Cisplatin-Cross-Linked and Oxygen-Resupply Hyaluronic Acid-Based Nanocarriers for Chemo-photodynamic Therapy

Correction to “hyaluronan Reduces Cationic Liposome-Induced Toxicity and Enhances the Antitumor Effect of Targeted Gene Delivery in Mice”

Frequency-dependent graded reflectivity mirror: characterization and laser implementation.

Correction to “identification of Tumor Specific Peptide As EpCAM Ligand and Its Potential Diagnostic and Therapeutic Clinical Application”

Retraction of “breast Cancer Chemo-immunotherapy Through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway”

Estrone-Conjugated PEGylated Liposome Co-Loaded Paclitaxel and Carboplatin Improve Anti-Tumor Efficacy in Ovarian Cancer and Reduce Acute Toxicity of Chemo-Drugs

Construction of ROS-Responsive Hyaluronic Acid Modified Paclitaxel and Diosgenin Liposomes and Study on Synergistic Enhancement of Anti-Ovarian Cancer Efficacy

A Novel Paclitaxel-Loaded Poly(ε-Caprolactone)/poloxamer 188 Blend Nanoparticle Overcoming Multidrug Resistance for Cancer Treatment

Programmed-response cross-linked nanocarrier for multidrug-resistant ovarian cancer treatment

High Cytotoxicity and Resistant-Cell Reversal of Novel Paclitaxel Loaded Micelles by Enhancing the Molecular-Target Delivery of the Drug

Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells

Paclitaxel Nanoparticle Inhibits Growth of Ovarian Cancer Xenografts and Enhances Lymphatic Targeting.